Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Avidity Biosciences, Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs), a novel RNA therapeutic platform combining monoclonal antibodies with oligonucleotides to target disease-causing RNA. Focused on rare neuromuscular diseases like myotonic dystrophy, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy, Avidity aims to deliver precise, scalable treatments addressing underlying genetic causes with improved tissue targeting and dosing convenience.
This description was generated via AI from an annual report. Updated about 1 year ago.